| Identification | Back Directory | [Name]
5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine | [CAS]
1610964-64-1 | [Synonyms]
PTC596
5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine
4,6-Pyrimidinediamine, 5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N4-[4-(trifluoromethyl)phenyl]-
5-Fluoro-2-(6-fluoro-2-methyl-1H-benzo[d]imidazol-1-yl)-N4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine | [Molecular Formula]
C19H13F5N6 | [MDL Number]
MFCD30489439 | [MOL File]
1610964-64-1.mol | [Molecular Weight]
420.34 |
| Chemical Properties | Back Directory | [Boiling point ]
583.9±60.0 °C(Predicted) | [density ]
1.55±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF:30.0(Max Conc. mg/mL);71.4(Max Conc. mM)
DMSO:30.0(Max Conc. mg/mL);71.4(Max Conc. mM)
Ethanol:5.0(Max Conc. mg/mL);11.9(Max Conc. mM) | [form ]
A crystalline solid | [pka]
2.65±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Unesbulin (PTC596) is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor. Unesbulin downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia (AML) cells. Unesbulin has anti-leukemic activity[1][2]. | [in vivo]
Unesbulin (PTC596; 5 mg/kg; oral gavage; every 3 days for 13 days) significantly prolongs mouse survival[1].
Unesbulin (20 mg/kg; oral gavage; once a week for 15 days) causes tumor volume significantly smaller than that of control SCID mice with K562 cells[1].
Unesbulin (10 or 12.5 mg/kg; oral gavage; twice a week until death) causes the survival significantly longer than the vehicle-treated group in NOD-SCID mice with HL-60 cells[1].
| Animal Model: | NOD-SCID/IL2Rγ-KO (NSG) mice with MOLM-13 cells[1] | | Dosage: | 5?mg/kg | | Administration: | Oral gavage; every 3 days for 13 days | | Result: | Significantly prolonged mouse survival compared with the vehicle-treated mice in a dose-dependent manner.
|
| [References]
[1] Nishida Y, et al. The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells. Blood Cancer J. 2017 Feb 17;7(2):e527. DOI:10.1038/bcj.2017.8
[2] BMI1 inhibitor PTC596 |
|
|